NCT04925063View on ClinicalTrials.gov

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

August 31, 2027

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Metformin

The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.

Trial Locations (1)

510060

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER